<ul><li>Adial Pharmaceuticals Inc ADIL.OQ ADIL.O is expected to show no change in quarterly revenue when it reports results on May 16 (estimated) for the period ending March 31 2025</li><li> </li><li>​LSEG's mean analyst estimate for Adial Pharmaceuticals Inc is for a loss of 49 cents per share. </li><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 2 &#34;strong buy&#34; or &#34;buy,&#34; 1 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34; </li><li>The mean earnings estimate of analysts was unchanged in the last three months. ​</li><li>Wall Street's median 12-month price target for Adial Pharmaceuticals Inc is $6.50​, above​ its last closing price of $0.63. ​​​</li></ul>This summary was machine generated May 14 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

ADIL

Adial Pharmaceuticals Inc is expected to report a loss of 49 cents per share for the quarter ending March 31, 2025, with no change in quarterly revenue. The average analyst rating is "buy," with a median 12-month price target of $6.50, significantly above its last closing price of $0.63. The earnings estimate has remained unchanged over the last three months.

Adial Pharmaceuticals Inc <Q> expected to post a loss of 49 cents a share - Earnings Preview